Table 2.

10-year outcomes for a cohort of 100,000 women of child-bearing age starting on EFV or NVP-based ART regimens in Côte d’Ivoire: base case analysis

	EFV	NVP	Δ (EFV-NVP)
Women
At 10 years, number of women:
Alive	68,880	67,969	911
Still on first-line regimen	24,585	23,121	1,464
With undetectable plasma HIV-1 RNA	65,144	64,613	531
Overall time on ART during child-bearing years, person-years	694,341	692,413	1,928
Including time on first-line ART (EFV or NVP)	456,153	430,748	25,405
Pregnancies and newborns
Pregnancies at 10 years, number	54,853	54,701	152
Abortions, miscarriages and stillbirths	12,945	12,909	36
Live births	41,908	41,791	117
Birth defects	1,187	1,128	59
Combined outcomes
Δ NWA per additional birth defect (1)			15
Equivalence birth defect rate difference (2)			3.4%

EFV: ART regimen including efavirenz and 2 nucleoside reverse transcriptase inhibitors (tenofovir + emtricitabine); NVP: ART regimen including nevirapine and 2 nucleoside reverse transcriptase inhibitors (tenofovir + emtricitabine);

⁽¹⁾

Δ NWA per additional birth defect = The ratio of number of women alive at ten years on EFV compared to NVP to the additional number of birth defects on EFV compared to NVP

$$=(\mathit{NWA}\_\mathit{EFV}-\mathit{NWA}\_\mathit{NVP})/(\mathit{NBD}\_\mathit{EFV}-\mathit{NBD}\_\mathit{NVP})$$

Where:

• NWA = number of women alive at 10 years
• NBD = number of birth defects over 10 years

⁽²⁾Equivalence birth defect rate difference: difference in birth defect rate per 100 live births between EFV and NVP that would be necessary to make the NWA at 10 years equivalent to the number of birth defects